The biochemical characterization of three highly toxic peptides from the venom of the marine snail Conus geographus is described in this report
The notable peptide vaccines that have undergone phase I/II/III clinical trials include HER-2/neu immunodominant peptide (lung, breast, or ovarian cancer) [6971], Mucin-1 (MUC-1, Stimuvax), peptide (breast or colon cancer) [72, 73], Carcinoembryonic antigen (colorectal, gastric, breast, pancreatic and non-small-cell lung cancers) [74, 75], Prostate-specific membrane antigen (prostate cancer) [7678], HPV-16 E7 peptide (cervical cancer) [79], Ras oncoprotein peptide (colorectal and pancreatic carcinomas) [8082], and Melanoma antigens (Melanoma) [62, 68, 8385]
Together, BPC's angiogenic and cytoprotective repair activity and KPV's intracellular NF-B suppression and antimicrobial defense provide a synergistic dual-peptide system specifically suited to gastrointestinal, immune, and inflammatory recovery protocols with skin and vascular tissue support dimensions
BPC 157 increased nitric oxide production and activated the eNOS phosphorylation as reported in our previous study 6
[11] Two magnesium ions function to stabilize the acylphosphate intermediate, facilitate binding of ATP, and activate removal of phosphate group from ATP
